(Q43919588)

28 November 2017

title

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia (English)

1 reference

28 November 2017

1 reference

4

1 reference

28 November 2017

Moti L Kashyap

1

1 reference

28 November 2017

Mark E McGovern

2

1 reference

28 November 2017

Kathleen Berra

3

1 reference

28 November 2017

Peter O Kwiterovich

5

1 reference

28 November 2017

Wayne L Harper

6

1 reference

28 November 2017

Phillip D Toth

7

1 reference

28 November 2017

Laurence K Favrot

8

1 reference

28 November 2017

Boris Kerzner

9

1 reference

28 November 2017

Stephen D Nash

10

1 reference

28 November 2017

Harold E Bays

11

1 reference

28 November 2017

Phillip D Simmons

12

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

American Journal of Cardiology

28 November 2017

published in

1 reference

28 November 2017

volume

89

1 reference

28 November 2017

issue

6

1 reference

28 November 2017

page(s)

672-678

1 reference

The benefits of niacin in atherosclerosis

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Regulatory concerns at various phases of drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Mechanism of action of niacin on lipoprotein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Treatment of hyperlipidemia with combined niacin-statin regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2801%2902338-4

10.1016/S0002-9149(01)02338-4

7 January 2021

Identifiers

DOI

1 reference

28 November 2017

1 reference